Key result
Prolonged administration of the KCa channel activator SKA-31 restored maximal endothelium-dependent aortic relaxation to 80.6% compared to 53.2% in vehicle-treated Apoe-/- mice, without altering fatty plaque formation.
Why the study?
Pharmacological enhancement of endothelial Ca2+-activated K+ channel activity opposes vascular dysfunction in ageing and type 2 diabetes, but its efficacy in atherogenesis required investigation.
Does the KCa channel activator SKA-31 improve endothelial function in atherosclerosis-prone Apoe-/- mice?
Does the KCa channel activator SKA-31 improve endothelial function in atherosclerosis-prone Apoe-/- mice?
Prolonged administration of the KCa channel activator SKA-31 improved endothelial function without modifying fatty plaque formation in an atherosclerosis-prone mouse model.
Answers are grounded in this paper and cite their sources.
SKA-31 may improve endothelial function in atherosclerosis models; hypothesis-generating and should not yet change practice.
Introduction Atherosclerosis remains a major risk factor for vascular dysfunction and cardiovascular (CV) disease. Pharmacological enhancement of endothelial Ca2+-activated K+ channel activity (i.e., KCa2.3 and KCa3.1) opposes vascular dysfunction associated with ageing and type 2 diabetes (T2D) in ex vivo and in vivo preparations. In the current study, we have investigated the efficacy of this strategy to mitigate endothelial dysfunction in the setting of atherogenesis. Methods Male apolipoprotein E knockout (Apoe−/−) mice fed a high fat diet (HFD) were treated daily with the KCa channel activator SKA-31 (10 mg/kg), the KCa3.1 channel blocker senicapoc (40 mg/kg), or drug vehicle for 12-weeks. Endothelium-dependent and -independent relaxation and vasocontractility were measured in abdominal aorta by wire myography. The development of atherosclerosis in the thoracic aorta was characterized by Oil Red O staining and immunohistochemistry. Key vasorelaxant signaling proteins were quantified by q-PCR. Results Endothelium-dependent relaxation of phenylephrine-constricted aortic rings was impaired in Apoe−/− HFD mice (53%) vs. wild-type (WT) controls (80%, P < 0.0001), consistent with endothelial dysfunction. Treatment of Apoe−/− HFD mice with SKA-31, but not senicapoc, restored maximal relaxation to the WT level. Phenylephrine-evoked contraction was similar in WT and vehicle/drug treated Apoe−/− mice, as was the maximal relaxation induced by the endothelium-independent vasodilator sodium nitroprusside. mRNA expression for eNOS, KCa3.1, KCa2.3 and TRPV4 channels in the abdominal aorta was unaffected by either SKA-31 or senicapoc treatment. Fatty plaque formation, tissue collagen, α-smooth muscle actin and resident macrophages in the aortic sinus were also unaltered by either treatment vs. vehicle treated Apoe−/− HFD mice. Conclusion Our data show that prolonged administration of the KCa channel activator SKA-31 improved endothelial function without modifying fatty plaque formation in the aorta of Apoe−/− mice.
No takes yet. Share an insight, caveat, or question.
Vera et al. (2025) studied Atherosclerosis (n=62). SKA-31 vs. Vehicle (Miglyol 812N) was evaluated on Maximal endothelium-dependent relaxation (Emax) of phenylephrine-constricted aortic rings to acetylcholine (p=<0.0001). Prolonged administration of the KCa channel activator SKA-31 restored maximal endothelium-dependent aortic relaxation to 80.6% compared to 53.2% in vehicle-treated Apoe-/- mice, without altering fatty plaque formation.
Synapse has enriched 10 related papers. Consider them for comparative context: